Top Page
MedAdvisor Limited
(Sydney:MDR)
MedAdvisor Limited (MDR) vs. iShares MSCI Australia ETF (EWA)
MedAdvisor Limited Business Overview & Revenue Model
MedAdvisor Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 122.11M | 97.96M | 67.75M | 38.77M | 9.60M |
| Gross Profit | 23.63M | 12.59M | -1.84M | -6.06M | -3.63M |
| EBITDA | 7.05M | -3.03M | -11.29M | -14.93M | -10.34M |
| Net Income | 792.13K | -11.31M | -17.35M | -13.95M | -9.58M |
Balance Sheet | |||||
| Total Assets | 98.78M | 95.91M | 78.44M | 80.92M | 21.27M |
| Cash, Cash Equivalents and Short-Term Investments | 15.58M | 14.20M | 7.58M | 7.15M | 12.35M |
| Total Debt | 12.61M | 13.09M | 13.41M | 9.16M | 1.42M |
| Total Liabilities | 47.20M | 47.45M | 43.89M | 32.07M | 4.25M |
| Stockholders Equity | 51.58M | 48.46M | 34.55M | 48.45M | 16.66M |
Cash Flow | |||||
| Free Cash Flow | 3.35M | -1.63M | -548.13K | -12.94M | -9.00M |
| Operating Cash Flow | 5.19M | -1.45M | -236.32K | -12.54M | -8.68M |
| Investing Cash Flow | -2.80M | -3.23M | -290.79K | -43.36M | 230.68K |
| Financing Cash Flow | -831.97K | 12.42M | 1.86M | 50.72M | 16.39M |
MedAdvisor Limited Technical Analysis
MedAdvisor Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | £4.81B | 6.73 | -62.36% | 5.45% | 34.03% | 6.31% | |
57 Neutral | AU$36.26M | 110.00 | -8.34% | ― | -5.27% | 50.29% | |
55 Neutral | AU$78.45M | ― | -11.80% | ― | 14.56% | 13.36% | |
55 Neutral | AU$147.72M | ― | -5.63% | ― | -11.96% | 7.50% | |
55 Neutral | AU$71.84M | ― | -457.46% | ― | 21.93% | 10.34% | |
47 Neutral | AU$18.95M | ― | -74.80% | ― | -9.16% | 89.23% |
MedAdvisor Limited Corporate Events
MedAdvisor Limited has announced the issuance of 19,826,251 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational dynamics and aligning staff interests with company growth objectives.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has appointed Mr. Sean Slattery as the new Chief Financial Officer and Company Secretary, effective July 21, 2025. Mr. Slattery, who previously served as CFO at Rhinomed Limited, will play a crucial role in MedAdvisor’s strategic review, which includes the potential sale of its U.S. business. His appointment comes at a pivotal time as the company seeks to unlock shareholder value. The transition will be facilitated by working alongside the current CFO, Ms. Ancila Desai, ensuring a smooth handover.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced the quotation of 469,046 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from July 14, 2025. This move reflects the company’s strategic efforts to enhance its financial positioning and potentially expand its market presence, offering implications for stakeholders regarding increased liquidity and investment opportunities.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
Jencay Capital Pty Limited, a substantial holder in MedAdvisor Limited, has increased its voting power from 7.24% to 8.39% by purchasing an additional 9,142,870 ordinary shares. This change in shareholding indicates a growing interest and confidence in MedAdvisor’s operations, potentially impacting the company’s market positioning and signaling positive implications for stakeholders.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced an investor webinar to discuss the sale of its ANZ operations and provide updates on its strategic options review process. This move could significantly impact the company’s operations and market positioning, as it seeks to streamline its focus and potentially enhance shareholder value.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has completed the sale of its ANZ business operations and related intellectual property to Jonas Software for an estimated total transaction value of $42.35 million. This strategic move allows MedAdvisor to focus on its US operations while maintaining its ASX listing. The transaction involves a $35 million headline price, with an additional earn-out potential of $7.35 million based on future performance. The sale will enable MedAdvisor to discharge its financial obligations and marks a significant shift in its operational focus. Additionally, the company’s CFO, Mrs. Ancila Desai, will be stepping down following the transaction.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has entered into a binding agreement to sell its ANZ business division and related intellectual property to Jonas Software AUS Pty Ltd for a headline price of $35 million, with potential additional earnings based on future performance. This strategic move will allow MedAdvisor to focus on its US operations, while the sale proceeds will be used to settle existing debts and potentially return capital to shareholders, pending post-completion adjustments.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced a change in the interests of its substantial holder, Guild Group Holdings Limited, which now holds 94,905,130 fully paid ordinary shares. This change reflects a reduction in Guild Group Holdings Limited’s voting power due to non-participation in a capital raising offer, while they participated in an entitlement offer, impacting their voting power from 18% to 15.19%.
The most recent analyst rating on (AU:MDR) stock is a Buy with a A$0.53 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited, a company in the healthcare technology sector, is known for its digital medication management solutions. Recently, Mercer Investments (Australia) Limited, acting as the responsible entity of the Mercer Australian Small Companies Fund, has ceased to be a substantial holder in MedAdvisor Limited as of May 16, 2025. This change involved the sale of 2,565,351 shares, potentially impacting MedAdvisor’s shareholder structure and market perception.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced the quotation of 389,420 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 20, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially strengthen its market position, which could have implications for its stakeholders and operations.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced a change in the interests of its substantial holder, EBOS Group Limited, which is a key player in the healthcare and pharmaceutical distribution industry. The announcement indicates a dilution in EBOS’s voting power from 9.81% to 8.65% due to the issuance of new shares by MedAdvisor, including a recent placement and share purchase plan. This change reflects a strategic adjustment in the company’s shareholder structure, potentially impacting its governance dynamics and stakeholder interests.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced the quotation of 26,680,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning positively.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has successfully completed its Share Purchase Plan (SPP), raising A$2.668 million, exceeding its initial target of A$2 million. This funding will support the company’s strategic initiatives and provide additional working capital, with the new shares set to begin trading on 16 May 2025. The company also plans to hold an Extraordinary General Meeting to approve shares committed by directors in a previous placement.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has entered into a non-binding Letter of Intent with a subsidiary of a major multinational software company to sell its ANZ business division and associated intellectual property. The potential transaction, valued at $35 million with an additional earn-out component, could significantly impact MedAdvisor’s operations and market positioning by aligning with a company that has a substantial market capitalization and revenue.
MedAdvisor Limited has requested a trading halt on its securities as it prepares to release an announcement regarding a strategic update. This halt is related to a non-binding proposal to acquire its ANZ business division, indicating potential significant changes in its operational focus and market strategy.
MedAdvisor Limited has received a non-binding Letter of Intent from a multinational software company to acquire its ANZ business division, which the directors believe offers a materially higher value than the current share price. This proposal aligns with MedAdvisor’s strategic review process aimed at bridging the valuation gap of its ANZ and US business units. The ANZ division recently achieved record revenue, and the potential acquirer plans to continue investing in the business, benefiting pharmacies across Australia. The transaction, subject to due diligence, is expected to be finalized within 5 to 7 weeks.
MedAdvisor Limited, listed on the Australian Securities Exchange (ASX) under the ticker MDR, has announced the lifting of its trading suspension. This follows the release of an announcement concerning the outcome of a Court application under section 1322 of the Corporations Act 2001, which allows the company to resume trading immediately.
MedAdvisor Limited has announced that the Federal Court of Australia granted their request to rectify an administrative oversight related to a late lodgement of a cleansing notice for shares issued in a recent placement. Following this court order, MedAdvisor has requested the resumption of trading in its securities, which had been voluntarily suspended. This development is expected to restore normal trading operations and maintain investor confidence.
MedAdvisor Limited has released an investor presentation update for the third quarter of FY25, emphasizing that the information provided is for general informational purposes and not intended as financial advice or an investment offer. The presentation includes disclaimers about the accuracy and completeness of the information, highlighting the potential risks and uncertainties associated with forward-looking statements, and advises recipients to conduct their own independent assessments.
MedAdvisor Limited reported a significant decline in its financial performance for 3Q FY25, with operating revenue and gross profit nearly halved compared to the previous year. Despite these challenges, the company is actively pursuing strategic initiatives to capitalize on evolving market trends, including cost optimization and restructuring its US operations. The company also completed a $5 million capital raise to support these initiatives, aiming for sustainable growth in FY26.
MedAdvisor Limited announced that its CEO, Rick Ratliff, and CFO, Ancila Desai, will present the company’s third-quarter FY25 results in a live webinar on April 30, 2025. This event is significant for stakeholders as it provides insights into the company’s operational performance and strategic direction, potentially impacting its market positioning and investor relations.
MedAdvisor Limited has requested a voluntary suspension of its securities from the Australian Securities Exchange (ASX) pending a court application. This action is to ensure that trading does not occur on an uninformed basis while the company seeks to validate a cleansing notice related to share issuance. The suspension will remain until the court’s decision or a further announcement by the company, expected by May 2, 2025.
MedAdvisor Limited has announced an extension to its Share Purchase Plan (SPP) deadline, moving it from April 30, 2025, to May 9, 2025. This extension aims to provide eligible shareholders additional time to participate and complete their applications, potentially impacting shareholder engagement and investment levels.
MedAdvisor Limited has requested a trading halt on its securities pending an important announcement related to a Court order under the Corporations Act. This halt will remain until the announcement is made or until normal trading resumes on April 29, 2025. The decision indicates a significant development that could impact the company’s operations or market positioning, though specific details are yet to be disclosed.